These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 22036653)

  • 1. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
    Le VN; Hoang Thi TH; Robins E; Flament MP
    Int J Pharm; 2012 Mar; 424(1-2):44-9. PubMed ID: 22207163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
    Flament MP; Leterme P; Gayot A
    Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH; Danède F; Descamps M; Flament MP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G; Leterme P; Gayot A; Flament MP
    Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN; Hoang Thi TH; Robins E; Flament MP
    AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3415-29. PubMed ID: 20222025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X; Li J; Wen X; Ma S; An Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2024 Oct; 664():124609. PubMed ID: 39163928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.